Belite Bio Reports First-Quarter 2023 Operational
In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease (“STGD1”) trial (“LBS-008-CT02”), we continued to observe that oral Tinlarebant is...
Source: globenewswire.com
Page 9 - Nasdaq Blte News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Blte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Blte Today - Breaking & Trending Today
Belite Bio to Host Webcast on May 11, 2023 to Discuss First
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on...
Source: globenewswire.com
Belite Bio to Host Key Opinion Leader Webinar Discussing
The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a...
Source: globenewswire.com
Belite Bio (NASDAQ:BLTE) Shares Gap Up to $27.59
Belite Bio, Inc (NASDAQ:BLTE – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $27.59, but opened at $29.20. Belite Bio shares last traded at $29.20, with a volume of 485 shares trading hands. Analyst Ratings Changes BLTE has been the subject of a number of analyst reports. […]
Source: modernreaders.com
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Grows By 13.6%
Belite Bio, Inc (NASDAQ:BLTE – Get Rating) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 31,700 shares, a growth of 13.6% from the March 31st total of 27,900 shares. Based on an average trading volume of 10,500 shares, the short-interest ratio is […]
Source: modernreaders.com